SPY319.34+8.04 2.58%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%

Roth Capital Initiates Coverage On Clearside Biomedical with Buy Rating, Announces Price Target of $8

Roth Capital analyst Zegbeh Jallah initiates coverage on Clearside Biomedical (NASDAQ:CLSD) with a Buy rating and announces Price Target of $8.

Benzinga · 05/13/2020 10:05

Roth Capital analyst Zegbeh Jallah initiates coverage on Clearside Biomedical (NASDAQ:CLSD) with a Buy rating and announces Price Target of $8.